Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N. Westin, Gordon B. Mills, Yong Fang et al.|Clinical Cancer Research|2021Cited by 76
Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancerShannon N. Westin, Gordon B. Mills, Marilyne Labrie et al.|medRxiv|2021Cited by 11